Breast Cancer: Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated
High Risk HER2 Negative Primary Breast Cancer (OlympiA)
Will adding treatment with olaparib after the usual care of chemotherapy, surgery
and radiation reduce the risk of the cancer coming back?
Basic Study Information
Purpose:Location: Cancer Center
The purpose of this study is to compare the addition of olaparib after the usual care
of chemotherapy, surgery, and radiation for your type of cancer. If your cancer is
sensitive to hormone treatment, you may receive hormone drugs as part of usual care.
In this study, you will get either olaparib or placebo, a pill that looks like the
study drug but contains no medication. The use of olaparib could reduce the risk
of your cancer coming back but it could also cause side effects.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02032823?term=NSABP+B55&rank=1
Study Reference #: CBRS-16133
Lead Researcher (Principal Investigator)
Lead Researcher: Alissa Huston
Study Contact InformationStudy Coordinator: Kate Corcoran
Phone: (585) 275-7771
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search